Pharmaceutical

Cara Therapeutics cuts 50% of staff and drops kidney disease program

The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.

Jan 23, 2024 - 18:00
Cara Therapeutics cuts 50% of staff and drops kidney disease program
The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.
Read the original article

Tags:

Previous Article

STAT+: Feds bar Theranos founder Elizabeth Holmes from government health programs

Next Article

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MABS-139 by Manhattan Biosolutions for Solid Tumor: Lik...

Dec 20, 2023

Free Covid tests will be offered again to all U.S. households

Free Covid tests will be offered again to all U.S. hous...

Sep 20, 2023

Oesophageal cancer: the global clinical trials landscape in 2024

Oesophageal cancer: the global clinical trials landscap...

Aug 29, 2024